<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment and prevention of venous thromboembolism in patients with brain tumors</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment and prevention of venous thromboembolism in patients with brain tumors</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment and prevention of venous thromboembolism in patients with brain tumors</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eudocia Quant Lee, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Y Wen, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lawrence LK Leung, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Treatment and prevention of venous thromboembolism (VTE) in patients with primary and metastatic brain tumors is complicated by two conflicting issues. Patients with brain tumors have a substantial risk for developing VTE due to a hypercoagulable state, neurosurgical procedures, and often leg paresis. However, there is concern that antithrombotic agents can precipitate hemorrhage into the tumor with neurologic worsening.</p><p>The balance between these issues is discussed here. The overall risk, diagnosis, and treatment of VTE in patients with malignancy, as well as risk and treatment of anticoagulant-associated intracerebral hemorrhage, are reviewed separately. (See  <a class="medical medical_review" href="/d/html/1340.html" rel="external">"Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy"</a> and  <a class="medical medical_review" href="/d/html/119889.html" rel="external">"Risks and prevention of bleeding with oral anticoagulants"</a> and  <a class="medical medical_review" href="/d/html/1325.html" rel="external">"Reversal of anticoagulation in intracranial hemorrhage"</a>.)</p><p class="headingAnchor" id="H319095405"><span class="h1">PRE-ANTICOAGULATION RISK ASSESSMENT</span></p><p class="headingAnchor" id="H934476647"><span class="h2">General principles</span><span class="headingEndMark"> — </span>The principles of managing acute VTE in patients with brain tumors are the same as in other patients with and without cancer. Anticoagulation is the cornerstone of treatment, and treatment decisions balance the risk of bleeding complications due to anticoagulation with the risks of untreated and recurrent VTE.</p><p>The risks of untreated VTE are substantial. Mortality associated with untreated pulmonary embolism is approximately 30 percent, usually due to recurrent embolism. Untreated, symptomatic deep vein thrombosis (DVT) carries a 50 percent risk of pulmonary embolism. (See  <a class="medical medical_review" href="/d/html/8253.html" rel="external">"Epidemiology and pathogenesis of acute pulmonary embolism in adults", section on 'Prognosis'</a> and  <a class="medical medical_review" href="/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Patients at low risk of bleeding'</a>.)</p><p>Patients with cancer have higher than usual rates of recurrent VTE as well as a higher risk of bleeding with anticoagulant therapy compared with the general population. Therapy can be further complicated by comorbidities, procedures, and medication interactions  (<a class="graphic graphic_table graphicRef81646" href="/d/graphic/81646.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/1340.html" rel="external">"Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy"</a>.)</p><p>For patients with brain tumors, an individual assessment of bleeding risk with anticoagulant therapy takes into account the following:</p><p class="bulletIndent1"><span class="glyph">●</span>General risk factors for bleeding at any site  (<a class="graphic graphic_table graphicRef97160" href="/d/graphic/97160.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Assessing bleeding risk'</a> and  <a class="medical medical_review" href="/d/html/119889.html" rel="external">"Risks and prevention of bleeding with oral anticoagulants", section on 'Risk factors for bleeding'</a> and  <a class="medical medical_review" href="/d/html/119889.html" rel="external">"Risks and prevention of bleeding with oral anticoagulants", section on 'Intracranial'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Risk factors for intracranial bleeding specifically, which may be influenced by the type of brain tumor, history of prior intracranial hemorrhage, recent craniotomy, and certain therapies. Each of these factors is discussed individually below.</p><p></p><p>Evidence-based guidelines on the treatment of acute VTE in cancer patients provide variable amounts of detail and specificity regarding brain tumors [<a href="#rid1">1-4</a>]. Our approach is generally consistent with these guidelines except as noted in the topic. Our recommendations for anticoagulation assume that treatment is in accordance with patient preferences with regard to goals of care and life expectancy.</p><p class="headingAnchor" id="H2674142801"><span class="h2">Type of brain tumor</span><span class="headingEndMark"> — </span>Brain tumors have varying propensities to hemorrhage spontaneously. In general, malignant tumors are more likely to bleed than benign tumors, and certain cancer types are associated with higher risk than others.</p><p class="bulletIndent1"><span class="glyph">●</span>Primary brain tumors – The rate of symptomatic bleeding into high-grade gliomas (eg, glioblastoma) is estimated at approximately 1 to 12 percent in the absence of antithrombotic therapy [<a href="#rid5">5-9</a>]. In observational studies, the risk of hemorrhage is several percentage points higher in patients receiving anticoagulation. (See <a class="local">'Safety'</a> below.)</p><p></p><p class="bulletIndent1">Spontaneous bleeding into benign or low-grade primary brain tumors occurs less commonly, although studies are lacking to provide precise estimates of the frequency of symptomatic intracranial hemorrhage. Among benign or low-grade tumors, pituitary adenomas may be especially prone to spontaneous intratumoral hemorrhage [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Brain metastases – Brain metastases from melanoma, choriocarcinoma, thyroid carcinoma, and renal cell carcinoma have particularly high propensities for spontaneous hemorrhage [<a href="#rid10">10</a>], while brain metastases from certain other primary tumors (eg, breast) generally do not bleed spontaneously. In one study, the risk of measurable intracranial hemorrhage over a one-year interval was fourfold higher in patients with brain metastases from renal cell carcinoma or melanoma compared with lung cancer [<a href="#rid11">11</a>]. The cumulative incidence of significant hemorrhage (defined as size &gt;10 mL, symptomatic, or requiring surgical intervention) in the absence of anticoagulation was 37 percent in patients with melanoma or renal cell cancer and 19 percent in patients with non-small cell lung cancer.</p><p></p><p class="headingAnchor" id="H3165727545"><span class="h2">Prior intracranial hemorrhage</span><span class="headingEndMark"> — </span>In the general adult population, patients with a history of spontaneous intracranial hemorrhage are at increased risk for recurrent hemorrhage. The annual risk is estimated at 1 to 7 percent, and recurrence is most common within the first year following hemorrhage [<a href="#rid12">12</a>]. The most important risk factors for recurrent intracranial hemorrhage are uncontrolled hypertension, lobar location of the initial hemorrhage (as opposed to deep), and older age. In patients who require anticoagulation, guidelines suggest delaying anticoagulants for at least four weeks after onset of hemorrhage [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/d/html/129071.html" rel="external">"Spontaneous intracerebral hemorrhage: Secondary prevention and long-term prognosis", section on 'Anticoagulation'</a>.)</p><p>Patients with a history of tumor-associated intracranial hemorrhage are likely to be at increased risk of recurrent hemorrhage as well, although this has not been well studied, and the population is more heterogeneous. In the absence of better data, it is reasonable to consider recurrence risk estimates from patients with spontaneous intracranial hemorrhage when making risk/benefit decisions in patients with brain tumors. Estimates of risk may be further individualized based on the status of the residual tumor, if present, and the clinical circumstances at the time of the index hemorrhage, including the presence or absence of additional risk factors for bleeding (eg, thrombocytopenia, antithrombotic therapy).</p><p class="headingAnchor" id="H868257446"><span class="h2">Microhemorrhage within tumor</span><span class="headingEndMark"> — </span>Evidence of microhemorrhage within tumors on susceptibility-weighted or proton density magnetic resonance imaging (MRI) sequences, without signal change on T1- or T2-weighted imaging, is common in patients with high-grade gliomas and brain metastases, especially melanoma. Susceptibility sequences are highly sensitive to the paramagnetic properties of hemosiderin, a breakdown product of blood. The changes may be variably described in radiology reports as susceptibility artifact, microhemorrhage, or chronic hemorrhage.</p><p>The significance of isolated susceptibility artifact within a tumor with regard to risk of clinical hemorrhage with or without anticoagulation has not been established in patients with brain tumors. While intuitively it raises concern that anticoagulation may pose a higher risk of tumor-related hemorrhage, this has not been well studied. In our clinical experience, the presence of microhemorrhage in isolation does not appear to be a contraindication in a patient who is otherwise deemed a candidate for anticoagulation.</p><p class="headingAnchor" id="H2534147825"><span class="h2">Treatment with antiangiogenic therapy</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">Bevacizumab</a> is a monoclonal antibody that binds to vascular endothelial growth factor and is used in the treatment of recurrent malignant glioma as well as other cancers. (See  <a class="medical medical_review" href="/d/html/5205.html" rel="external">"Management of recurrent high-grade gliomas", section on 'Bevacizumab'</a>.)</p><p><a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">Bevacizumab</a> is associated with both an increased risk of VTE and an increased risk of bleeding complications. (See  <a class="medical medical_review" href="/d/html/14250.html" rel="external">"Cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Arterial and venous thromboembolism'</a> and  <a class="medical medical_review" href="/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Bleeding'</a>.)</p><p>Limited data in patients with malignant glioma who are treated with <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> and anticoagulation suggest that although the risk of intracerebral hemorrhage is increased in patients receiving anticoagulants compared with those who are not, the risk-to-benefit ratio favors concurrent therapy in many cases [<a href="#rid14">14,15</a>]. (See  <a class="medical medical_review" href="/d/html/5205.html" rel="external">"Management of recurrent high-grade gliomas", section on 'Side effects'</a>.)</p><p>In a retrospective review of 38 malignant glioma patients treated with <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>, VTE developed in five patients (13 percent) and was preceded four weeks before the onset of symptoms by D-dimer elevation above 865 ng/mL [<a href="#rid16">16</a>]. An existing hemiparesis conferred the highest risk for thrombotic complication.</p><p>In patients with brain metastases, there does not appear to be a significant increase in the risk of hemorrhage with use of <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>. (See  <a class="medical medical_review" href="/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Intracranial bleeding'</a>.)</p><p class="headingAnchor" id="H3740726652"><span class="h1">THERAPEUTIC ANTICOAGULATION</span><span class="headingEndMark"> — </span>Anticoagulation is the cornerstone of treatment for acute VTE for patients with and without cancer, including most patients with intracranial tumors.</p><p>Historically, patients with primary or metastatic brain tumors and VTE were often managed with the placement of inferior vena cava (IVC) filters rather than with anticoagulation because of concern over an increased risk of symptomatic intratumoral hemorrhage [<a href="#rid17">17-20</a>]. However, practice has evolved, and anticoagulation is now generally preferred in many cases because the incidence of complications with IVC filters is higher than originally thought, and the risk of intracranial hemorrhage secondary to anticoagulation, although elevated overall compared with no anticoagulation [<a href="#rid21">21,22</a>], is not as high as once feared.</p><p class="headingAnchor" id="H761034232"><span class="h2">Absolute contraindications</span><span class="headingEndMark"> — </span>Absolute contraindications to anticoagulation include acute (&lt;48 hours) intracranial hemorrhage, uncontrolled malignant hypertension, severe coagulopathy, severe platelet dysfunction, severe thrombocytopenia, inherited bleeding disorder, and high-risk invasive intracranial procedure within the last 7 to 14 days [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Patients at high risk of bleeding'</a>.)</p><p class="headingAnchor" id="H1038943390"><span class="h2">Relative contraindications</span><span class="headingEndMark"> — </span>Most brain tumors do not pose a prohibitive risk of hemorrhage in patients with VTE who are otherwise appropriate candidates for anticoagulation, and the treatment approach is the same as in other patients with cancer. (See  <a class="medical medical_review" href="/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)"</a> and  <a class="medical medical_review" href="/d/html/1340.html" rel="external">"Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy"</a>.)</p><p>The primary exceptions are patients with a history of intratumoral hemorrhage and those with tumors that have a high rate of spontaneous intracranial hemorrhage (ie, metastases from melanoma, choriocarcinoma, thyroid carcinoma, and renal cell carcinoma). In such patients, decisions must be individualized, as each of these factors represents a relative contraindication to anticoagulation that must be weighed against the risk of untreated VTE. (See <a class="local">'Pre-anticoagulation risk assessment'</a> above.)</p><p>Selected patients may be reasonable candidates for anticoagulation, such as those with surgically resected disease or otherwise effectively treated brain metastases [<a href="#rid11">11</a>]. Anticoagulation can also be considered even in patients with cancers that have a greater propensity for hemorrhage (ie, melanoma, choriocarcinoma, thyroid carcinoma, and renal cell carcinoma), provided that there is no evidence of acute intracranial hemorrhage on imaging and the potential benefits outweigh the risks. In a meta-analysis of retrospective studies, the risk of intracerebral hemorrhage was not significantly elevated in patients with brain metastases from melanoma or renal cell carcinoma who were treated with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> and/or low molecular weight (LMW) heparin [<a href="#rid21">21</a>].</p><p>We generally avoid anticoagulation in patients with intratumoral hemorrhage within the past four weeks or a remote history of a clinically significant intracranial hemorrhage. We do not consider the presence of microhemorrhage on MRI to be a contraindication to anticoagulation for VTE, in the absence of additional risk factors for bleeding. (See <a class="local">'Prior intracranial hemorrhage'</a> above and <a class="local">'Microhemorrhage within tumor'</a> above.)</p><p class="headingAnchor" id="H1931391748"><span class="h2">Agent selection</span><span class="headingEndMark"> — </span>Based on accumulating safety data in brain tumor patients as well as convenience, our approach to agent selection in patients who require anticoagulation for VTE is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>For most patients, we suggest use of a direct oral anticoagulant (DOAC) rather than LMW heparin or <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>. (See <a class="local">'Direct oral anticoagulants'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who cannot take a DOAC due to reasons such as cost, we suggest LMW heparin rather than <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> for maintenance. (See <a class="local">'Low molecular weight heparin'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with severe renal insufficiency (eg, creatinine clearance &lt;30 mL/minute), options include either renally-dosed LMW heparin with monitoring of anti-factor Xa activity or <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>. (See <a class="local">'Low molecular weight heparin'</a> below and <a class="local">'Warfarin'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thrombolysis is contraindicated in patients with an intracranial malignancy. (See  <a class="medical medical_review" href="/d/html/8259.html" rel="external">"Approach to thrombolytic (fibrinolytic) therapy in acute pulmonary embolism: Patient selection and administration"</a>.)</p><p></p><p>For most patients, a DOAC or LMW heparin are appropriate for both immediate (ie, first five days) and continued anticoagulation. We prefer to use <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a> initially in patients who are clinically unstable and in patients at very high risk of bleeding, based on the short half-life of heparin and the ability to reverse rapidly with <a class="drug drug_general" data-topicid="9831" href="/d/drug information/9831.html" rel="external">protamine sulfate</a>. (See  <a class="medical medical_review" href="/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects", section on 'Unfractionated heparin'</a>.)</p><p>There are no randomized trials directly comparing DOACs, LMW heparin, and/or <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> anticoagulation specifically in patients with brain tumors. However, a growing body of observational data in these patients suggests that DOACs have similar efficacy and lower major bleeding risk compared with LMW heparin (see <a class="local">'Direct oral anticoagulants'</a> below). In addition, indirect evidence drawn from randomized trials in cancer patients (mostly without brain metastases) suggests that DOACs are associated with similar or lower VTE recurrence rates and similar or slightly increased major bleeding rates compared with LMW heparin, and that LMW heparin is more effective for recurrent VTE than warfarin with similar rates of bleeding. These data are reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/1340.html" rel="external">"Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy"</a>.)</p><p class="headingAnchor" id="H3635357132"><span class="h2">Safety</span></p><p class="headingAnchor" id="H3613450190"><span class="h3">Direct oral anticoagulants</span><span class="headingEndMark"> — </span>The available data and our accumulating clinical experience suggest that DOACs are an effective, convenient, and probably safer alternative to LMW heparin for brain tumor patients who require anticoagulation [<a href="#rid23">23-29</a>]. Nonetheless, all of the data on comparative risk of intracranial hemorrhage in this patient population are retrospective, and in the absence of randomized trials, we acknowledge ongoing uncertainty for this endpoint.</p><p>Evidence in patients with glioblastoma includes a single-center retrospective cohort study of 121 patients diagnosed with VTE who were treated with a DOAC (n = 33) or LMW heparin (n = 88) [<a href="#rid27">27</a>]. At 30 days, the incidence of clinically relevant intracranial hemorrhage was nonsignificantly lower in patients treated with a DOAC compared with LMW heparin (0 versus 9 percent, p = 0.11). At six months, among 107 patients who were maintained on their initial anticoagulant, the cumulative incidence of clinically relevant intracranial hemorrhage was significantly lower in the DOAC group (0 versus 24 percent, p = 0.001), with four fatal hemorrhages in the LMW heparin group. Rates of recurrent VTE were similar between groups (0 and 4 percent for DOACs and LMW heparin, respectively, p = 0.55). Patient characteristics appeared balanced between groups with the exception of time since most recent surgery, which was shorter in the LMW heparin group, and concurrent use of an antiplatelet agent, which was nonsignificantly higher in the DOAC group.</p><p>Other retrospective data in patients with brain metastases and various primary brain tumors have shown similar results favoring DOACs. In a retrospective study of patients with primary (n = 67) or metastatic (n = 105) brain tumors with VTE who were anticoagulated with either a DOAC or LMW heparin, the 12-month incidence of major intracranial hemorrhage was lower with DOACs in patients with primary brain tumors (0 versus 18 percent) as well as brain metastases (11 versus 18 percent), although the difference was not statistically significant for brain metastases [<a href="#rid24">24</a>]. In both the primary and metastatic brain tumor comparisons, patients in the DOAC group were more likely to have baseline hypertension, chronic kidney disease, and concomitant <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> use. In a second retrospective study that included 96 patients with brain metastases treated with either a DOAC or LMW heparin, the adjusted risk of any intracranial hemorrhage was similar between DOAC- and LMW heparin-treated patients (HR 0.98, 95% CI 0.28-3.40) [<a href="#rid25">25</a>]. In a third study that included 52 brain tumor patients treated with a DOAC, the risk of any major bleeding was higher in association with LMW heparin, and the risk of intracranial hemorrhage was nonsignificantly lower with DOACs [<a href="#rid26">26</a>].</p><p>In trials comparing DOACs with LMW heparin for initial treatment of cancer-associated VTE, most or all patients did not have brain metastases at baseline. Available data on intracranial hemorrhage and brain metastases in these trials are reviewed below:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="99275" href="/d/drug information/99275.html" rel="external">Edoxaban</a>, an oral factor Xa inhibitor, was compared with <a class="drug drug_general" data-topicid="9319" href="/d/drug information/9319.html" rel="external">dalteparin</a> in 1050 patients with active cancer and VTE, of which 74 patients had a primary or metastatic brain tumor [<a href="#rid30">30</a>]. The trial showed a nonsignificant reduction in the rate of recurrent thrombosis in the edoxaban arm but a higher rate of major bleeding, mostly from gastrointestinal bleeding and predominantly in patients with primary gastrointestinal malignancies. The rate of serious bleeding, which included intracranial hemorrhage, was equal between the groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">Rivaroxaban</a>, an oral factor Xa inhibitor, was compared with <a class="drug drug_general" data-topicid="9319" href="/d/drug information/9319.html" rel="external">dalteparin</a> in 406 patients with active cancer and VTE, but only three patients had a brain tumor [<a href="#rid31">31</a>]. Rivaroxaban was associated with relatively low VTE recurrence but higher clinically relevant nonmajor bleeding compared with dalteparin. No central nervous system (CNS) bleeds were reported on study.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">Apixaban</a>, another oral factor Xa inhibitor, was compared with <a class="drug drug_general" data-topicid="9319" href="/d/drug information/9319.html" rel="external">dalteparin</a> in 287 cancer patients with acute symptomatic or incidental VTE [<a href="#rid32">32</a>]. This trial enrolled eight patients with brain tumors, but the number of patients with brain metastases was not explicitly reported. VTE recurrence rate was significantly lower in the apixaban arm, and the rate of major bleeding was similar in the two treatment groups. In a larger trial comparing apixaban versus dalteparin, there were no brain tumor patients, and major bleeding rates were similar between groups [<a href="#rid33">33</a>]. There was one fatal intracranial hemorrhage in the dalteparin group.</p><p></p><p>DOACs are convenient because they do not require injections or drug level monitoring. US Food and Drug Administration (FDA)-approved antidotes or specific reversal agents for the DOACs are now available, though routine coagulation tests cannot be used to determine the degree of anticoagulation. (See  <a class="medical medical_review" href="/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants"</a> and  <a class="medical medical_review" href="/d/html/1340.html" rel="external">"Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy"</a>.)</p><p class="headingAnchor" id="H1949660047"><span class="h3">Low molecular weight heparin</span><span class="headingEndMark"> — </span>The best available estimate of the risk of major hemorrhage in brain tumor patients treated with LMW heparin is derived from a retrospective case control study of 364 patients with cancer-associated VTE, half of whom had a primary or metastatic brain tumor [<a href="#rid34">34</a>]. Anticoagulation consisted of extended-duration therapeutic LMW heparin in approximately 90 percent of patients. With a median follow-up of 6.7 months, the incidence of major bleeding was similar in patients with and without brain tumors (8.6 versus 5.0 per 100 patient-years). The rate of intracranial hemorrhage in patients with brain tumors was 4.4 percent; seven of nine hemorrhages were symptomatic and none were fatal. There were no intracranial hemorrhages in the control group.</p><p>Most but not all smaller studies have found similar results:</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective matched cohort study of 293 patients with brain metastases in which approximately one-third of the patients received therapeutic <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a>, there was no significant difference in the cumulative incidence of intracranial hemorrhage at one year in patients treated with enoxaparin compared with controls who were not (19 versus 21 percent for measurable hemorrhage, 21 versus 22 percent for significant hemorrhage, and 44 versus 37 percent for total hemorrhages) [<a href="#rid11">11</a>]. The risk of hemorrhage was fourfold higher in patients with melanoma or renal cell carcinoma compared with lung cancer (adjusted hazard ratio [HR] 3.98, 95% CI 2.41-6.57), but the risk was not affected by anticoagulation status.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of 64 patients with glioblastoma who were diagnosed with VTE, 93 percent of patients were treated with anticoagulation, mostly LMW heparin [<a href="#rid35">35</a>]. The majority of patients were treated for &gt;6 months. Ten patients (16 percent) developed complications due to anticoagulation, including three patients with brain hemorrhage (4.7 percent) and three with extracranial bleeding.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective cohort study that included 50 patients with a primary brain tumor (mostly glioblastoma) treated with <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a> for VTE identified a higher rate of intracranial hemorrhage (14.7 versus 2.5 percent not treated with anticoagulation) [<a href="#rid36">36</a>]. Neither hypertension nor use of an antiangiogenic agent were risk factors for hemorrhage; older age at diagnosis approached statistical significance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A larger retrospective study in 220 patients with high-grade glioma found a similarly high risk of measurable intracranial hemorrhage in patients treated with LMW heparin for VTE (17 percent one-year cumulative incidence), which was not statistically different than the cumulative incidence in patients not receiving anticoagulation, both with VTE (9 percent) and without VTE (13 percent) [<a href="#rid9">9</a>]. Approximately two-thirds of the hemorrhages were associated with symptoms.</p><p></p><p class="headingAnchor" id="H1219941712"><span class="h3">Warfarin</span><span class="headingEndMark"> — </span>Studies of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> in patients with brain tumors also indicate that the risk of tumor-associated intracranial hemorrhage may not be significantly increased in patients with primary or metastatic brain tumors if the degree of anticoagulation with warfarin is carefully monitored [<a href="#rid6">6,17,18,37-40</a>].</p><p class="headingAnchor" id="H515201105"><span class="h2">Dosing</span><span class="headingEndMark"> — </span>Dosing for DOACs, LMW heparin, <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a>, and <a class="drug drug_general" data-topicid="8691" href="/d/drug information/8691.html" rel="external">fondaparinux</a> in the treatment of VTE is discussed separately. (See  <a class="medical medical_review" href="/d/html/95336.html" rel="external">"Venous thromboembolism: Initiation of anticoagulation"</a>.)</p><p class="headingAnchor" id="H23528522"><span class="h2">Duration of therapy</span><span class="headingEndMark"> — </span>Patients with acute VTE should be treated for at least three to six months. Extended or lifelong therapy is suggested in most patients with glioblastoma and other forms of active cancer, including those receiving antitumor therapy, as well as in patients with recurrent VTE, provided the bleeding risk is low and no clinically relevant complications from anticoagulation have occurred. (See  <a class="medical medical_review" href="/d/html/1340.html" rel="external">"Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy"</a>.)</p><p>Duration of therapy in patients without active malignancy (eg, patients with low-grade gliomas or benign brain tumors such as meningioma) should be individualized based on an assessment of risk of recurrence, risk of bleeding, and patient values and preferences. (See  <a class="medical medical_review" href="/d/html/94740.html" rel="external">"Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Role of inferior vena cava filter</span><span class="headingEndMark"> — </span>While IVC filters should not be routinely inserted in patients with acute deep vein thrombosis (DVT), they remain in use for patients deemed to have a prohibitive risk of bleeding with anticoagulation and life-threatening thrombus burden [<a href="#rid1">1</a>].</p><p>The efficacy of IVC filters for prevention of recurrent pulmonary embolism in patients with brain tumors is not well characterized. In the general population, observational data indicate that rates of recurrent pulmonary embolism are low (&lt;5 percent in most series). (See  <a class="medical medical_review" href="/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Inferior vena cava filter'</a>.)</p><p>In small studies, the use of IVC filters in patients with brain tumors has been associated with higher risk of recurrent VTE and variable complication rates [<a href="#rid17">17,37</a>]. In an older series of 42 such patients, 12 percent had recurrent pulmonary emboli and 57 percent developed IVC or filter thrombosis, recurrent DVT, or post-thrombotic syndrome [<a href="#rid17">17</a>]. A more modern series reported a 30 percent rate of recurrent VTE in 60 patients with glioblastoma who had an IVC filter placed, some of whom also received anticoagulation [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/d/html/8212.html" rel="external">"Placement of vena cava filters and their complications"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">PRIMARY PREVENTION (VTE PROPHYLAXIS)</span></p><p class="headingAnchor" id="H2812657480"><span class="h2">Incidence and risk factors</span><span class="headingEndMark"> — </span>Patients with primary or metastatic brain tumors, as well as malignancies at other sites, have a latent hypercoagulable state that predisposes to thromboembolism, particularly in the postoperative period [<a href="#rid42">42-44</a>]. (See  <a class="medical medical_review" href="/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer"</a> and  <a class="medical medical_review" href="/d/html/1353.html" rel="external">"Cancer-associated hypercoagulable state: Causes and mechanisms"</a>.)</p><p>Estimates of the incidence of VTE consistently show increased relative risk among patients with cancer compared with the general population, particularly in patients with glioblastoma [<a href="#rid45">45</a>]. In prospective studies of patients with malignant glioma, the observed incidence of symptomatic VTE ranges from 17 to 26 percent [<a href="#rid5">5,46-48</a>].</p><p>Although there is clustering of VTE events in the postoperative period following craniotomy and during intensive chemotherapy, the risk persists throughout the clinical course [<a href="#rid44">44</a>]. Risk factors for VTE in patients with brain tumors include [<a href="#rid16">16,35,43,44,49-52</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Older age (≥60 years)</p><p class="bulletIndent1"><span class="glyph">●</span>Low performance status</p><p class="bulletIndent1"><span class="glyph">●</span>Obesity</p><p class="bulletIndent1"><span class="glyph">●</span>Glioblastoma histology and absence of an isocitrate dehydrogenase type 1 or 2 (<em>IDH1/2</em>) mutation</p><p class="bulletIndent1"><span class="glyph">●</span>Large tumor size (eg, &gt;5 cm) and subtotal resection</p><p class="bulletIndent1"><span class="glyph">●</span>Use of steroids, <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>, and/or chemotherapy</p><p class="bulletIndent1"><span class="glyph">●</span>Recent neurosurgery (within the past two months)</p><p class="bulletIndent1"><span class="glyph">●</span>Leg paresis or plegia</p><p class="bulletIndent1"><span class="glyph">●</span>A or AB blood type</p><p></p><p>For adults with diffuse gliomas, a VTE prediction tool has been developed based on a cohort of 258 adults with newly-diagnosed grade 2 to 4 diffuse glioma, in which the incidence of VTE was 18 percent [<a href="#rid53">53</a>]. Multivariable modeling verified many of the above risk factors and was used to generate a 10-item tool, which predicted high versus low VTE risk with moderate accuracy in validation cohorts (areas under the curve [AUCs] ranging from 0.63 to 0.84). A web-based version of the tool is available [<a href="#rid54">54</a>]. However, since it is based on relatively low AUCs and has not been prospectively validated, it should not be used as a stand-alone tool to make clinical decisions about preventive treatment.</p><p class="headingAnchor" id="H3694709895"><span class="h2">Inpatients and postoperative patients</span><span class="headingEndMark"> — </span>Perioperatively, the frequency of VTE in brain tumor patients is approximately 10 to 15 percent [<a href="#rid43">43,55,56</a>]. The use of pneumatic compression stockings combined with low molecular weight (LMW) heparin or unfractionated subcutaneous heparin started preoperatively and resumed 24 to 48 hours after surgery is effective and relatively safe in neurosurgical patients [<a href="#rid57">57-61</a>]. These measures are generally continued until the patient resumes ambulation.</p><p class="headingAnchor" id="H3138281063"><span class="h2">Outpatients</span><span class="headingEndMark"> — </span>Primary prophylaxis with anticoagulants is <strong>not</strong> generally recommended in ambulatory patients with brain tumors except in the perioperative period [<a href="#rid52">52,62</a>].</p><p>The extended use of LMW heparin (<a class="drug drug_general" data-topicid="9319" href="/d/drug information/9319.html" rel="external">dalteparin</a>) as primary prophylaxis of VTE in patients with newly diagnosed malignant glioma was assessed in the PRODIGE trial [<a href="#rid5">5</a>]. The trial was terminated prematurely because of the unavailability of placebo. Overall, 186 patients were randomly assigned to six months of treatment with dalteparin or placebo, with an option to continue on study medication for up to 12 months. The incidence of clinically evident VTE at six months was lower among those receiving dalteparin (11 versus 17 percent with placebo), but the difference was not statistically significant. Intracranial hemorrhages were more common in patients treated with dalteparin (5 versus 1 percent with placebo at 12 months; hazard ratio [HR] 4.2, 95% CI 0.48-36).</p><p>The PRODIGE trial confirmed the substantial risk of VTE in patients with malignant gliomas. Although there were trends toward reduction of VTE and increase in intracranial hemorrhage, the trial did not have adequate statistic power at the time of termination to draw definitive conclusions about the benefits versus risks of long-term anticoagulation.</p><p>A small phase II trial involving 40 patients with malignant gliomas treated with the LMW heparin <a class="drug drug_general" data-topicid="10009" href="/d/drug information/10009.html" rel="external">tinzaparin</a> 4500 international units subcutaneously daily for a median of approximately five months reported symptomatic central nervous system (CNS) hemorrhage in one patient (2.5 percent) and deep vein thrombosis (DVT) in one patient (2.5 percent) [<a href="#rid63">63</a>].</p><p>For the prevention of VTE in at-risk patients with brain tumors, long-term treatment with daily <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> (eg, 325 mg/day orally) may offer partial protection and is easy to administer, although neither the safety nor efficacy of this approach has been well defined in this population [<a href="#rid40">40</a>]. For general VTE prevention, aspirin appears to have some activity, but it is clearly less than that afforded by anticoagulation [<a href="#rid64">64</a>]. (See  <a class="medical medical_review" href="/d/html/94740.html" rel="external">"Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation"</a>.)</p><p><a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">Aspirin</a> therapy may be considered for primary prevention of VTE in brain tumor patients who are ≥60 years old, have large tumors or substantial leg weakness, or are undergoing chemotherapy. However, the effect of aspirin in inhibiting platelet function in patients at risk for chemotherapy-induced thrombocytopenia must be weighed against the limited evidence of benefit in preventing VTE.</p><p class="headingAnchor" id="H2847745287"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/114614.html" rel="external">"Society guideline links: Anticoagulation"</a> and  <a class="medical medical_society_guidelines" href="/d/html/130511.html" rel="external">"Society guideline links: Primary brain tumors"</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/689.html" rel="external">"Patient education: Warfarin (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/693.html" rel="external">"Patient education: Deep vein thrombosis (DVT) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – The general principles of managing acute venous thromboembolism (VTE) in patients with brain tumors are the same as in other patients with and without cancer. Anticoagulation is the cornerstone of treatment, and treatment decisions balance the risk of bleeding complications due to anticoagulation with the risks of untreated and recurrent VTE. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment risk assessment</strong> – The risk of bleeding in patients with brain tumors is determined by considering both general risk factors for bleeding with anticoagulant therapy  (<a class="graphic graphic_table graphicRef97160" href="/d/graphic/97160.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef81646" href="/d/graphic/81646.html" rel="external">table 1</a>) and risk of intracranial hemorrhage related to the tumor and any antitumor therapies. (See <a class="local">'Pre-anticoagulation risk assessment'</a> above.)</p><p></p><p class="bulletIndent1">Absolute contraindications to anticoagulation in patients with and without brain tumors include acute intracranial hemorrhage (&lt;48 hours), uncontrolled malignant hypertension, severe coagulopathy, severe platelet dysfunction or thrombocytopenia, inherited bleeding disorder, and recent intracranial surgery. (See <a class="local">'Absolute contraindications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Therapeutic anticoagulation</strong> – Most brain tumors do not pose a prohibitive risk of hemorrhage in patients with VTE who are otherwise appropriate candidates for anticoagulation. Potential exceptions include brain metastases from melanoma, choriocarcinoma, thyroid carcinoma, and renal cell carcinoma, which have a higher rate of spontaneous intratumoral hemorrhage than other tumor types, and patients with a history of intratumoral hemorrhage. Decisions in these patients should be individualized. (See <a class="local">'Relative contraindications'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Agent selection</strong> – In patients with brain tumors who are selected to receive anticoagulation for VTE, we suggest a direct oral anticoagulant (DOAC) rather than low molecular weight (LMW) heparin or <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). For patients who cannot take a DOAC due to cost, we suggest LMW heparin rather than warfarin for maintenance (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). For patients with severe renal insufficiency, options include renally-dosed LMW heparin with monitoring of anti-factor Xa activity or warfarin. (See <a class="local">'Agent selection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Duration</strong> – VTE in low-grade glioma and benign tumors should be treated for three to six months, whereas long-term anticoagulation is generally indicated for patients with glioblastoma and other active malignancies. (See <a class="local">'Duration of therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of inferior vena cava (IVC) filter</strong> – IVC filters should not be routinely inserted in brain tumor patients with acute deep vein thrombosis (DVT). However, they remain in use for patients deemed to have a prohibitive risk of bleeding with anticoagulation and life-threatening thrombus burden. (See <a class="local">'Role of inferior vena cava filter'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prophylactic anticoagulation</strong> – Although patients with primary or metastatic brain tumors are at relatively high risk for the development of VTE, we suggest that these patients not be anticoagulated prophylactically, except in the postoperative period (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Primary prevention (VTE prophylaxis)'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Key NS, Khorana AA, Kuderer NM, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 2020; 38:496.</a></li><li><a class="nounderline abstract_t">Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013; 11:56.</a></li><li><a class="nounderline abstract_t">Khorana AA, Noble S, Lee AYY, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost 2018; 16:1891.</a></li><li class="breakAll">NCCN guidelines on cancer-associated venous thromboembolic disease. https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/vte.pdf.</li><li><a class="nounderline abstract_t">Perry JR, Julian JA, Laperriere NJ, et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 2010; 8:1959.</a></li><li><a class="nounderline abstract_t">Ruff RL, Posner JB. Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol 1983; 13:334.</a></li><li><a class="nounderline abstract_t">Wakai S, Yamakawa K, Manaka S, Takakura K. Spontaneous intracranial hemorrhage caused by brain tumor: its incidence and clinical significance. Neurosurgery 1982; 10:437.</a></li><li><a class="nounderline abstract_t">Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014; 370:709.</a></li><li><a class="nounderline abstract_t">Jo J, Donahue J, Sarai G, et al. Management of venous thromboembolism in high-grade glioma: Does low molecular weight heparin increase intracranial bleeding risk? Neuro Oncol 2022; 24:455.</a></li><li><a class="nounderline abstract_t">Mandybur TI. Intracranial hemorrhage caused by metastatic tumors. Neurology 1977; 27:650.</a></li><li><a class="nounderline abstract_t">Donato J, Campigotto F, Uhlmann EJ, et al. Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study. Blood 2015; 126:494.</a></li><li><a class="nounderline abstract_t">Poon MT, Fonville AF, Al-Shahi Salman R. Long-term prognosis after intracerebral haemorrhage: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2014; 85:660.</a></li><li><a class="nounderline abstract_t">Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2015; 46:2032.</a></li><li><a class="nounderline abstract_t">Nghiemphu PL, Green RM, Pope WB, et al. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol 2008; 10:355.</a></li><li><a class="nounderline abstract_t">Norden AD, Bartolomeo J, Tanaka S, et al. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. J Neurooncol 2012; 106:121.</a></li><li><a class="nounderline abstract_t">Misch M, Czabanka M, Dengler J, et al. D-dimer elevation and paresis predict thromboembolic events during bevacizumab therapy for recurrent malignant glioma. Anticancer Res 2013; 33:2093.</a></li><li><a class="nounderline abstract_t">Levin JM, Schiff D, Loeffler JS, et al. Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology 1993; 43:1111.</a></li><li><a class="nounderline abstract_t">Olin JW, Young JR, Graor RA, et al. Treatment of deep vein thrombosis and pulmonary emboli in patients with primary and metastatic brain tumors. Anticoagulants or inferior vena cava filter? Arch Intern Med 1987; 147:2177.</a></li><li><a class="nounderline abstract_t">Wen PY, Marks PW. Medical management of patients with brain tumors. Curr Opin Oncol 2002; 14:299.</a></li><li><a class="nounderline abstract_t">Norris LK, Grossman SA. Treatment of thromboembolic complications in patients with brain tumors. J Neurooncol 1994; 22:127.</a></li><li><a class="nounderline abstract_t">Zwicker JI, Karp Leaf R, Carrier M. A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation. J Thromb Haemost 2016; 14:1736.</a></li><li><a class="nounderline abstract_t">Wood P, Boyer G, Mehanna E, et al. Intracerebral haemorrhage in patients with brain metastases receiving therapeutic anticoagulation. J Neurol Neurosurg Psychiatry 2021.</a></li><li><a class="nounderline abstract_t">Riedl J, Ay C. Venous Thromboembolism in Brain Tumors: Risk Factors, Molecular Mechanisms, and Clinical Challenges. Semin Thromb Hemost 2019; 45:334.</a></li><li><a class="nounderline abstract_t">Carney BJ, Uhlmann EJ, Puligandla M, et al. Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors. J Thromb Haemost 2019; 17:72.</a></li><li><a class="nounderline abstract_t">Leader A, Hamulyák EN, Carney BJ, et al. Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases. Blood Adv 2020; 4:6291.</a></li><li><a class="nounderline abstract_t">Swartz AW, Drappatz J. Safety of Direct Oral Anticoagulants in Central Nervous System Malignancies. Oncologist 2021; 26:427.</a></li><li><a class="nounderline abstract_t">Reed-Guy L, Desai AS, Phillips RE, et al. Risk of intracranial hemorrhage with direct oral anticoagulants vs low molecular weight heparin in glioblastoma: A retrospective cohort study. Neuro Oncol 2022; 24:2172.</a></li><li><a class="nounderline abstract_t">Giustozzi M, Proietti G, Becattini C, et al. ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis. Blood Adv 2022; 6:4873.</a></li><li><a class="nounderline abstract_t">Giustozzi M, Becattini C, Roila F, et al. DOACs in patients with brain cancers: promising but still a long way to go. Blood Adv 2023; 7:283.</a></li><li><a class="nounderline abstract_t">Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med 2018; 378:615.</a></li><li><a class="nounderline abstract_t">Young AM, Marshall A, Thirlwall J, et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol 2018; 36:2017.</a></li><li><a class="nounderline abstract_t">McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost 2020; 18:411.</a></li><li><a class="nounderline abstract_t">Agnelli G, Becattini C, Meyer G, et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med 2020; 382:1599.</a></li><li><a class="nounderline abstract_t">Chai-Adisaksopha C, Linkins LA, ALKindi SY, et al. Outcomes of low-molecular-weight heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumours. Thromb Haemost 2017; 117:589.</a></li><li><a class="nounderline abstract_t">Yust-Katz S, Mandel JJ, Wu J, et al. Venous thromboembolism (VTE) and glioblastoma. J Neurooncol 2015; 124:87.</a></li><li><a class="nounderline abstract_t">Mantia C, Uhlmann EJ, Puligandla M, et al. Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin. Blood 2017; 129:3379.</a></li><li><a class="nounderline abstract_t">Schiff D, DeAngelis LM. Therapy of venous thromboembolism in patients with brain metastases. Cancer 1994; 73:493.</a></li><li><a class="nounderline abstract_t">Choucair AK, Silver P, Levin VA. Risk of intracranial hemorrhage in glioma patients receiving anticoagulant therapy for venous thromboembolism. J Neurosurg 1987; 66:357.</a></li><li><a class="nounderline abstract_t">Altschuler E, Moosa H, Selker RG, Vertosick FT Jr. The risk and efficacy of anticoagulant therapy in the treatment of thromboembolic complications in patients with primary malignant brain tumors. Neurosurgery 1990; 27:74.</a></li><li><a class="nounderline abstract_t">Quevedo JF, Buckner JC, Schmidt JL, et al. Thromboembolism in patients with high-grade glioma. Mayo Clin Proc 1994; 69:329.</a></li><li><a class="nounderline abstract_t">Edwin NC, Khoury MN, Sohal D, et al. Recurrent venous thromboembolism in glioblastoma. Thromb Res 2016; 137:184.</a></li><li><a class="nounderline abstract_t">Gerber DE, Grossman SA, Streiff MB. Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol 2006; 24:1310.</a></li><li><a class="nounderline abstract_t">Semrad TJ, O'Donnell R, Wun T, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 2007; 106:601.</a></li><li><a class="nounderline abstract_t">Jenkins EO, Schiff D, Mackman N, Key NS. Venous thromboembolism in malignant gliomas. J Thromb Haemost 2010; 8:221.</a></li><li><a class="nounderline abstract_t">Perry JR. Thromboembolic disease in patients with high-grade glioma. Neuro Oncol 2012; 14 Suppl 4:iv73.</a></li><li><a class="nounderline abstract_t">Ay C, Vormittag R, Dunkler D, et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2009; 27:4124.</a></li><li><a class="nounderline abstract_t">Brandes AA, Scelzi E, Salmistraro G, et al. Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study. Eur J Cancer 1997; 33:1592.</a></li><li><a class="nounderline abstract_t">Streiff MB, Ye X, Kickler TS, et al. A prospective multicenter study of venous thromboembolism in patients with newly-diagnosed high-grade glioma: hazard rate and risk factors. J Neurooncol 2015; 124:299.</a></li><li><a class="nounderline abstract_t">Streiff MB, Segal J, Grossman SA, et al. ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas. Cancer 2004; 100:1717.</a></li><li><a class="nounderline abstract_t">Mir Seyed Nazari P, Riedl J, Preusser M, et al. Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism. J Thromb Haemost 2018; 16:1121.</a></li><li><a class="nounderline abstract_t">Diaz M, Jo J, Smolkin M, et al. Risk of Venous Thromboembolism in Grade II-IV Gliomas as a Function of Molecular Subtype. Neurology 2021; 96:e1063.</a></li><li><a class="nounderline abstract_t">Jo J, Diaz M, Horbinski C, et al. Epidemiology, biology, and management of venous thromboembolism in gliomas: An interdisciplinary review. Neuro Oncol 2023; 25:1381.</a></li><li><a class="nounderline abstract_t">Burdett KB, Unruh D, Drumm M, et al. Determining venous thromboembolism risk in patients with adult-type diffuse glioma. Blood 2023; 141:1322.</a></li><li class="breakAll">Burdett, Kristen Bell. VTE Prediction for Patients with Glioma. 2022. Available at: https://kbellburdett.shinyapps.io/GliomaPredictVTE/ (Accessed on May 04, 2023).</li><li><a class="nounderline abstract_t">Chan AT, Atiemo A, Diran LK, et al. Venous thromboembolism occurs frequently in patients undergoing brain tumor surgery despite prophylaxis. J Thromb Thrombolysis 1999; 8:139.</a></li><li><a class="nounderline abstract_t">Smith TR, Lall RR, Graham RB, et al. Venous thromboembolism in high grade glioma among surgical patients: results from a single center over a 10 year period. J Neurooncol 2014; 120:347.</a></li><li><a class="nounderline abstract_t">Agnelli G, Piovella F, Buoncristiani P, et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 1998; 339:80.</a></li><li><a class="nounderline abstract_t">Iorio A, Agnelli G. Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. Arch Intern Med 2000; 160:2327.</a></li><li><a class="nounderline abstract_t">Constantini S, Kanner A, Friedman A, et al. Safety of perioperative minidose heparin in patients undergoing brain tumor surgery: a prospective, randomized, double-blind study. J Neurosurg 2001; 94:918.</a></li><li><a class="nounderline abstract_t">Alshehri N, Cote DJ, Hulou MM, et al. Venous thromboembolism prophylaxis in brain tumor patients undergoing craniotomy: a meta-analysis. J Neurooncol 2016; 130:561.</a></li><li><a class="nounderline abstract_t">Khan NR, Patel PG, Sharpe JP, et al. Chemical venous thromboembolism prophylaxis in neurosurgical patients: an updated systematic review and meta-analysis. J Neurosurg 2018; 129:906.</a></li><li><a class="nounderline abstract_t">Schmidt F, Faul C, Dichgans J, Weller M. Low molecular weight heparin for deep vein thrombosis in glioma patients. J Neurol 2002; 249:1409.</a></li><li><a class="nounderline abstract_t">Perry SL, Bohlin C, Reardon DA, et al. Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. J Neurooncol 2009; 95:129.</a></li><li><a class="nounderline abstract_t">Hovens MM, Snoep JD, Tamsma JT, Huisman MV. Aspirin in the prevention and treatment of venous thromboembolism. J Thromb Haemost 2006; 4:1470.</a></li></ol></div><div id="topicVersionRevision">Topic 5201 Version 46.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31381464" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23217107" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30027649" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30027649" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20598077" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6303201" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Incidence and treatment of peripheral venous thrombosis in patients with glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7099393" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Spontaneous intracranial hemorrhage caused by brain tumor: its incidence and clinical significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24552318" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34383073" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Management of venous thromboembolism in high-grade glioma: Does low molecular weight heparin increase intracranial bleeding risk?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/559971" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Intracranial hemorrhage caused by metastatic tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25987658" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24262916" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Long-term prognosis after intracerebral haemorrhage: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26022637" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18436627" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Safety of anticoagulation use and bevacizumab in patients with glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21706358" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23645760" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : D-dimer elevation and paresis predict thromboembolic events during bevacizumab therapy for recurrent malignant glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8170553" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Complications of therapy for venous thromboembolic disease in patients with brain tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3500686" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Treatment of deep vein thrombosis and pulmonary emboli in patients with primary and metastatic brain tumors. Anticoagulants or inferior vena cava filter?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11981275" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Medical management of patients with brain tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7745465" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Treatment of thromboembolic complications in patients with brain tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27306689" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33687972" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Intracerebral haemorrhage in patients with brain metastases receiving therapeutic anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31041803" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Venous Thromboembolism in Brain Tumors: Risk Factors, Molecular Mechanisms, and Clinical Challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30450803" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33351124" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33523555" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Safety of Direct Oral Anticoagulants in Central Nervous System Malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35551405" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Risk of intracranial hemorrhage with direct oral anticoagulants vs low molecular weight heparin in glioblastoma: A retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35772127" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36453644" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : DOACs in patients with brain cancers: promising but still a long way to go.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29231094" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29746227" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31630479" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32223112" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28078351" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Outcomes of low-molecular-weight heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25985958" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Venous thromboembolism (VTE) and glioblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28468796" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8293418" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Therapy of venous thromboembolism in patients with brain metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3819830" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Risk of intracranial hemorrhage in glioma patients receiving anticoagulant therapy for venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2377284" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The risk and efficacy of anticoagulant therapy in the treatment of thromboembolic complications in patients with primary malignant brain tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8170176" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Thromboembolism in patients with high-grade glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26657302" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Recurrent venous thromboembolism in glioblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16525187" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Management of venous thromboembolism in patients with primary and metastatic brain tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17432710" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Epidemiology of venous thromboembolism in 9489 patients with malignant glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19912518" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Venous thromboembolism in malignant gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23095833" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Thromboembolic disease in patients with high-grade glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19636003" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9389920" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26100546" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A prospective multicenter study of venous thromboembolism in patients with newly-diagnosed high-grade glioma: hazard rate and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15073862" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29676036" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33361259" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Risk of Venous Thromboembolism in Grade II-IV Gliomas as a Function of Molecular Subtype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37100086" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Epidemiology, biology, and management of venous thromboembolism in gliomas: An interdisciplinary review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36399711" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Determining venous thromboembolism risk in patients with adult-type diffuse glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36399711" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Determining venous thromboembolism risk in patients with adult-type diffuse glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10436144" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Venous thromboembolism occurs frequently in patients undergoing brain tumor surgery despite prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25062669" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Venous thromboembolism in high grade glioma among surgical patients: results from a single center over a 10 year period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9654538" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10927730" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11409520" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Safety of perioperative minidose heparin in patients undergoing brain tumor surgery: a prospective, randomized, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27591773" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Venous thromboembolism prophylaxis in brain tumor patients undergoing craniotomy: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29192859" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Chemical venous thromboembolism prophylaxis in neurosurgical patients: an updated systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12382158" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Low molecular weight heparin for deep vein thrombosis in glioma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19415455" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16839339" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Aspirin in the prevention and treatment of venous thromboembolism.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
